Revised Indications for the Use of Palivizumab and Respiratory Syncytial Virus Immune Globulin Intravenous for the Prevention of Respiratory Syncytial Virus Infections

Pediatrics

Volumn 112, Issue 6 I, 2003, Pages 1447-1452

  Meissner, H Cody ^a   Long, Sarah S ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BRONCHODILATING AGENT; PALIVIZUMAB; PLACEBO; RESPIRATORY SYNCYTIAL VIRUS ANTIBODY;

ARTIFICIAL VENTILATION; CHILD; CHRONIC LUNG DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DRUG EFFICACY; DRUG HYPERSENSITIVITY; HUMAN; INFANT; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY TRACT INFECTION; REVIEW; TREATMENT INDICATION; TREATMENT OUTCOME; VIRUS INFECTION;

ANTIBODIES, MONOCLONAL; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS; CORONARY DISEASE; COST-BENEFIT ANALYSIS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; INFANT; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUSES; RISK FACTORS;

EID: 0346816503     PISSN: 00314005     EISSN: None     Source Type: Journal    
DOI: 10.1542/peds.112.6.1447     Document Type: Review

References (22)

1. Groothuis JR, Simoes EA, Levin MJ, et al. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group. N Engl J Med. 1993;329:1524-1530
2. The PREVENT Study Group. Reduction of RSV hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. Pediatrics. 1997;99:93-99
3. The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics. 1998;102:531-537
4. Feltes TM, Cabala AK, Meissner HC, et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr. 2003;143:532-540
5. American Academy of Pediatrics, Committee on Infectious Diseases and Committee on Fetus and Newborn. Respiratory syncytial virus immune globulin intravenous: indications for use. Pediatrics. 1997;99:645-650
6. American Academy of Pediatrics, Committee on Infectious Diseases and Committee on Fetus and Newborn. Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV. Pediatrics. 1998;102:1211-1216
7. Simoes EA, Groothuis JR, Tristram DA, et al. Respiratory syncytial virus-enriched globulin for the prevention of acute otitis media in high-risk children. J Pediatr. 1996;129:214-219
8. Simoes EAF, Sondheimer HM, Top FH Jr, et al. Respiratory syncytial virus immune globulin for prophylaxis against respiratory syncytial virus disease in infants and children with congenital heart disease. The Cardiac Study Group. J Pediatr. 1998;133:492-499
9. Johnson S, Oliver C, Prince GA, et al. Development of humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J Infect Dis. 1997;176:1215-1224
10. Subramanian SKN, Weisman LE, Rhodes T, et al. Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. MED1-493 Study Group. Pediatr Infect Dis J. 1998;17:110-115
11. Palivizumab [package insert]. Gaithersburg, MD: MedImmune, Inc; 2002
12. Sorrentino M, Powers T. Effectiveness of pilivizumab: evaluation of outcomes from the 1998 to 1999 respiratory syncytial virus season. The Palivizumab Outcomes Study Group. Pediatr Infect Dis J. 2000;19:1068-1071
13. Oh PI, Lanctjt KL, Yoon A, et al. Palivizumab prophylaxis for RSV in Canada: utilization and outcomes. Pediatr Infect Dis J. 2002;21:512-518
14. Hay JW, Ernst RL, Meissner HC. RSV-IGIV: a cost effectiveness analysis. Am J Manag Care. 1996;2:851-861
15. O'Shea TM, Sevick MA, Givner LB. Costs and benefits of respiratory syncytial virus immunoglobulin to prevent hospitalization for lower respiratory tract illness in very low birth weight infants. Pediatr Infect Dis J. 1998;17:587-593
16. Robbins JM, Tilford JM, Jacobs RF, Wheeler JG, Gillaspy SR, Schutze GE. A number-needed-to-treat analysis of respiratory syncytial virus immune globulin intravenous to prevent hospitalization. Arch Pediatr Adolesc Med. 1998;152:358-366
17. Atkins JT, Karimi P, Morris BH, McDavid G, Shim S. Prophylaxis for RSV with RSV-IGIV among preterm infants of thirty-two weeks gestation and less: reduction in incidence, severity of illness and cost. Pediatr Infect Dis J. 2002;19:138-143
18. Thomas M, Bedford-Russell A, Sharland M. Hospitalisation for RSV infection in ex-preterm infants: implications for use of RSV-IGIV. Arch Dis Child. 2000;83:122-127
19. Joffe S, Ray GT, Escobar GJ, Black SB, Lieu TA. Cost-effectiveness of RSV prophylaxis among preterm infants. Pediatrics. 1999;104:419-427
20. Stevens TP, Sinkin RA, Hall CB, Maniscalco WM, McConnochie KM. Respiratory syncytial virus and premature infants born at 32 weeks' gestation or earlier: hospitalization and economic implications of prophylaxis. Arch Pediatr Adolesc Med. 200;154:55-61
21. Kamal-Bahl, S, Doshi J, Campbell J. Economic analysis of respiratory syncytial virus immunoprophylaxis in high-risk infants. Arch Pediatr Adolesc Med. 2002;156:1034-1041
22. American Academy of Pediatrics, Committee on Infectious Diseases and Committee on Fetus and Newborn. Policy statement: revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. Pediatrics. 2003;112:1442-1446